S.Korea's Celltrion in talks for stake sale
SEOUL Jan 2 (Reuters) - South Korea's Celltrion Inc said in a regulatory filing on Thursday that its largest shareholder is in talks with an interested party or parties to sell a controlling stake in the biotech firm.
Celltrion received European backing to sell a copycat version of the blockbuster rheumatoid arthritis drug Remicade last year.
Celltrion chose JP Morgan to advise on the sale last year, after its president said he will seek a buyer among multinational drugmakers for the controlling interest in the firm.
A spokesman for Celltrion declined to comment on the names or number of the interested party or parties.
(Reporting by Joyce Lee; Editing by Matt Driskill)